Clinical Trials Logo

Pituitary Tumor clinical trials

View clinical trials related to Pituitary Tumor.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05338125 Terminated - Pituitary Adenoma Clinical Trials

Electrophysiology of the Human Pituitary Gland

Start date: December 10, 2020
Phase: N/A
Study type: Interventional

Measurment of electrophysiological properties of the human pituitary gland during removal of a pituitary adenoma. Assessment if these properties are sufficient for intra-operative identification of different tissues.

NCT ID: NCT04106531 Terminated - Pituitary Tumor Clinical Trials

Validation of a Quality of Life Metric "Prolac-10"

Prolac-10
Start date: October 15, 2019
Phase:
Study type: Observational

This is a short-term validation study of a quality of life metric "Prolac-10" for patients diagnosed with a prolactinoma, undergoing new medical therapy.

NCT ID: NCT02749227 Terminated - Pituitary Tumor Clinical Trials

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

PASSILCORT
Start date: July 10, 2017
Phase: Phase 2
Study type: Interventional

This is a phase II, open-label, 12-month pilot study in 10 patients with silent corticotroph pituitary tumors testing the hypotheses that Pasireotide long-acting release (LAR) treatment of patients with silent corticotroph pituitary tumors and elevated plasma Proopiomelanocortin (POMC) levels will reduce plasma POMC levels and this will be associated with a reduction in pituitary tumor size. Pasireotide LAR 40 mg will be administered monthly. Baseline and monthly visits on therapy will monitor plasma levels of POMC, other pituitary function, safety labs, glucose tolerance, physical examination, and visual fields. Pituitary magnetic resonance imaging (MRI) will be done at baseline, 6 months and 12 months of therapy. The eligible patient population will consist of adult patients with known silent corticotroph pituitary tumors and elevated plasma levels of POMC.

NCT ID: NCT00646308 Terminated - Clinical trials for Growth Hormone Deficiency

Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas

Start date: March 2008
Phase: N/A
Study type: Observational

The purpose of this study is to determine if patients with a history of nonsecreting pituitary adenomas with untreated GH deficient patients have profiles consistent with increased cardiovascular risk compared to patients without GH deficiency who have undergone similar surgery.